February 17, 2023
Resistance to colistin, an antibiotic often viewed as a last-resort therapy against multi-drug-resistant Gram-negative bacteria (GNB), has emerged in Enterobacteriaceae species. One Health Trust and collaborators traced the history of colistin resistance and analyzed the impact of regulatory policies on colistin use on the prevalence of resistant E. coli using a One Health approach. Since the discovery of mcr-1, a plasmid-mediated colistin resistance gene, regulations, and policies have been created to maintain some of colistin’s efficacy. These measures have resulted in a steep decline in colistin production and the prevalence of colistin-resistant E. coli between 2016 and 2019.
Find the article, “Colistin: from the shadows to a One Health approach for addressing antimicrobial resistance” in the International Journal of Antimicrobial Agents here.
